Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

March 10, 2011

Otsuka Pharmaceutical Received Approval for Additional Indication of L-Cartin^® tablets for Carnitine Deficiency in Japan

Tokyo, Japan, March 10, 2011 -- Otsuka Pharmaceutical Co., Ltd. today announced that it received an approval for Additional Indication of L-Cartin^® tablets (nonproprietary name: levocarnitine chloride) for carnitine deficiency.

Latest Pharmaceutical Business related News Releases

17 APR 2023

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

30 JAN 2023

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

10 JAN 2023

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Received Approval for Additional Indication of L-Cartin® tablets for Carnitine Deficiency in Japan

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Otsuka Pharmaceutical Received Approval for Additional Indication of L-Cartin^® tablets for Carnitine Deficiency in Japan

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan